|
04-12-2010, 02:05 PM
|
|||
|
|||
Peregrine Launches Investigator-Sponsored Trial Program
TUSTIN, CA--(Marketwire - 04/12/10) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM - News ), a clinical-stage biopharmaceutical company developing first-in-class phosphatidylserine (PS)-targeting monoclonal antibodies for the treatment of cancer and viral infections, today announced the launch of an investigator-sponsored trial (IST) program for bavituximab and Cotara. Bavituximab is a novel ...
    
|
 |
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| CSC launches new educational program to enhance lymphoma patient, physician communica | cancerfr | Non-Hodgkin Lymphoma | 0 | 09-14-2010 09:25 PM |
| Cancer center launches 'mole mapping' program | cancerfr | Melanoma | 0 | 08-25-2010 02:27 AM |
| Neotropix Announces Enrollment of Patients in NCI-Sponsored Phase II Clinical Trial f | cancerfr | Lung Cancer | 0 | 05-14-2010 01:57 PM |
| Researchers launch NIH-sponsored clinical trial for spinal deformity | cancerfr | Vaginal Cancer | 0 | 05-08-2010 09:14 AM |
| Twitter launches ad program | cancerfr | Mesothelioma | 0 | 04-13-2010 05:26 PM |
Linear Mode
